Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹6,329 Cr
verified against source
Revenue YoY
18%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Cipla delivered a strong Q1 FY24 with 18% YoY revenue growth to INR 6,329 crore, driven by record performance in India (12% growth) and the US ($222 million, +43% YoY). EBITDA margin expanded to 23.6%, aided by favorable mix and operational efficiencies. PAT stood at INR 996 crore (15.7% of sales). The US complex portfolio, including Lanreotide (18% market share) and stabilized Albuterol, powered growth, while India's chronic share rose to 60%. Management raised full-year EBITDA margin guidance to ~23% (from 22% earlier). Key pipeline catalysts include Symbicort filing by year-end, 4-5 peptide launches over two years, and de-risking of Advair and Abraxane. Risks include US FDA classification for Indore facility and potential pricing pressure in the US generics market.
Colored figures show movement against the previous available record.
Guidance to track
- Management raised FY24 EBITDA margin guidance to approximately 23%, up from earlier 22% guidance, driven by strong Q1 performance and confidence across markets.
- Cipla expects to file generic Symbicort (respiratory product) by the end of calendar year 2023.
- Cipla plans to launch 4-5 peptide products over the next two years, with a couple of new peptide filings in the same period.
- Generic Advair is being transferred to an in-house facility; launch expected within 12 months with no incremental generic competition anticipated.
Risks flagged
- Cipla awaits US FDA classification for its Indore facility, which was audited in February 2023. This could impact approvals for key products like generic Advair.
- Cipla faced an Albuterol recall in Q1 and experienced a market share decline in Q4 FY23, though management states share has stabilized.
- While price erosion has eased, management noted it could revert to higher levels in later quarters, impacting US revenue sustainability.
- Cipla's Goa facility is under remediation and expects re-inspection in H2 FY24. Any adverse outcome could disrupt supply of key products.
Key quotes
- Our differentiated portfolio in U.S. continues to deliver strong growth for the franchise. The business yet again achieved its highest sales in the quarter by realizing a revenue of $222 million, growing by a strong 43% over the last year.
- We expect the full year EBITDA to be trending towards 23% for the year.
- I think our base level will be somewhere in the range of 210-215. I mean, what I meant by 210-215 was what we will be reporting, broadly going forward, quarter by quarter.
Research modules